<DOC>
	<DOC>NCT01454349</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.</brief_summary>
	<brief_title>Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Lower Urinary Tract Symptoms (LUTS) attributable to BPH for ≥6 months Written informed consent prior to enrollment in the study IPSS ≥12 Prostate volume of 30 100 mL as determined by TRUS Maximum urine flow (Qmax) of 4 15 mL/sec Refractory, intolerant or refused the use of alphablockers and/or 5 alphareductase inhibitors Unwilling or unable to undergo conventional surgical or available minimally invasive treatments Blood PSA values &lt;10 ng/mL Inability to void at least 125 mL of urine PVR volume &gt;200 mL Presence of or history of certain conditions that could interfere with study results or endanger subject Use of certain prescribed medications that could interfere with study results</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged prostate</keyword>
	<keyword>Lower urinary tract symptoms (LUTS)</keyword>
</DOC>